Skip to main content

Table 1 Characteristics of women with metastatic hormone receptor positive breast cancer and tumor genomic profile N = 267

From: Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

 

N

%

Age at Primary Dx

  < 40

54

20.2

 40–49

101

37.8

 50–59

69

25.8

  ≥ 60

43

16.1

Stage at Primary Dx

 1

62

23.2

 2

131

49.1

 3

59

22.1

 Unknown

16

5.6

Grade at Primary Diagnosis

 1

26

9.7

 2

135

50.6

 3

81

30.3

 9 (unknown)

25

9.4

 ER +

262

98.1

 PR+

218

81.7

 Chemotherapy Use

214

80.1

Body Mass Index

  < 25

61

22.8

 25–29.9

54

32.5

  > =30

51

30.7

 Missing

101

37.8

PIK3CA mutated

97

36.3

Medication use between primary and metastatic dx

 Aspirin

54

20.2

 NSAIDs

85

31.8

 Aspirin or NSAIDs

108

40.4

 Statins

34

12.7

 Betablockers

26

9.7

Typical Aspirin Dose among users

 325mg

15

27.8

 81mg

28

51.8

 Missing

11

20.4

Time to Metastasis

  < 5 years

129

48.3

 5–10 years

66

24.7

  ≥ 10 years

72

27.0